1.
J Med Chem
; 43(20): 3596-613, 2000 Oct 05.
Article
in English
| MEDLINE
| ID: mdl-11020274
ABSTRACT
A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents such as adamantylmethyl at N-1 and resolution of the racemic ureas resulted in our lead compound GV150013.
Subject(s)
Anti-Anxiety Agents/chemical synthesis , Benzodiazepines/chemical synthesis , Receptors, Cholecystokinin/antagonists & inhibitors , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/pharmacology , Benzodiazepines/chemistry , Benzodiazepines/pharmacology , Callithrix , Cerebral Cortex/metabolism , Crystallography, X-Ray , Guinea Pigs , HeLa Cells , Humans , In Vitro Techniques , Membranes , Mice , Models, Molecular , Pancreas/metabolism , Radioligand Assay , Rats , Receptor, Cholecystokinin A , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/metabolism , Stereoisomerism , Structure-Activity Relationship
2.
Arch Pharm (Weinheim)
; 330(11): 353-7, 1997 Nov.
Article
in English
| MEDLINE
| ID: mdl-9431027